Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07209098 · ClinicalTrials.gov registry record
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure
A clinical trial of Heart Failure and Reduced Ejection Fraction and NYHA Class III Heart Failure, sponsored by Impulse Dynamics.
- Recruiting
- Registry status
- 4,200
- Enrollment target
- 1
- Study location
NCT07209098: Recruiting study of Heart Failure and Reduced Ejection Fraction and NYHA Class III Heart Failure, sponsored by Impulse Dynamics.
NCT07209098 is a study of Heart Failure and Reduced Ejection Fraction and NYHA Class III Heart Failure that is actively recruiting participants, run by Impulse Dynamics. The registered enrollment target is 4,200 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07209098, a study of Heart Failure and Reduced Ejection Fraction and NYHA Class III Heart Failure, is actively recruiting participants, sponsored by Impulse Dynamics.
- RECRUITING
- Registry status
- 4,200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this prospective, multi-center, propensity-matched coverage with evidence development (CED) study is to assess the impact of cardiac contractility modulation (CCM) on mortality and heart failure hospitalizations in Medicare-eligible patients with heart failure who meet indications for CCM.
Primary Outcome
Time from index date to the first occurrence of either heart failure-related hospitalization or death in patients with a clinical indication for cardiac contractility modulation (CCM) therapy. Outcomes will be compared between patients implanted with the Optimizer System (treatment arm) and a propensity score-matched control group of patients who are eligible for CCM but did not receive the device. Data will be collected from a large, de-identified, multi-system electronic health record database
Conditions Studied
Interventions
- DEVICE Cardiac Contractility Modulation (CCM)
Study Locations (1)
New Jersey
- Impulse Dynamics - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,200 participants |
| Start Date | 2025-11 |
| Est. Completion | 2031-04 |
What NCT07209098 shows while recruiting
NCT07209098 is an observational study that tracks outcomes without assigning an intervention. Its 4,200 participants enrollment target places it among the larger protocols in the corpus.
The record links to 2 conditions, with Heart Failure and Reduced Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which Cardiac Contractility Modulation (CCM) is the first listed.
NCT07209098 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT07209098 about?
NCT07209098 is a clinical study titled "Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure". The purpose of this prospective, multi-center, propensity-matched coverage with evidence development (CED) study is to assess the impact of cardiac contractility modulation (CCM) on mortality and heart failure hospitalizations in Medicare-eligible patients with heart failure who meet indications for...
What is the current status of trial NCT07209098?
This trial is currently recruiting. The enrollment target is 4,200 participants. The study started on 2025-11. Estimated completion is 2031-04.
What conditions does trial NCT07209098 study?
This clinical trial studies the following conditions: Heart Failure and Reduced Ejection Fraction, NYHA Class III Heart Failure.
What interventions are being tested in trial NCT07209098?
The interventions under investigation include: Cardiac Contractility Modulation (CCM) (DEVICE).
Who is sponsoring clinical trial NCT07209098?
This trial is sponsored by Impulse Dynamics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07209098 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure and Reduced Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- NCT05969028 · 4,200 participants · NA
First Responder Airway & Compression Rate Trial
- NCT06935370 · 4,200 participants · Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
- NCT06492616 · 4,220 participants · Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia